Evidence map›Paper›PMID 41945933›Full record

SynthesisAsian Pacific journal of cancer prevention : APJCP2026

Performance of [68Ga]Ga-FAPI PET in Breast, Ovarian, and Cervical Cancers: A Systematic Review and Meta-Analysis.

Madina Gabdullina, Akmaral Ainakulova, Umut Elboga, Indira Karibayeva, Galymzhan Alisherov, Zhanar Zhakenova, Jandos Amankulov, Zhamilya Zholdybay

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Madina GabdullinaDepartment of Visual Diagnostics, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Akmaral AinakulovaDepartment of Visual Diagnostics, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Umut ElbogaDepartment of Nuclear Medicine, Faculty of Medicine, Gaziantep University, Gaziantep, Turkiye.
Indira KaribayevaDepartment of Health Policy and Community Health, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, USA.
Galymzhan AlisherovDepartment of Visual Diagnostics, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Zhanar ZhakenovaDepartment of Visual Diagnostics, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Jandos AmankulovDepartment of Visual Diagnostics, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Zhamilya ZholdybayDepartment of Visual Diagnostics, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis meta-analysis aims to evaluate the diagnostic efficacy of [68Ga]Ga-FAPI PET imaging in breast, ovarian, and cervical cancers by conducting a systematic review of the existing literature.

methodsA systematic review of PubMed, Web of Science, Scopus, and Google Scholar databases, following by a meta-analysis of the included studies, was performed using a random-effects statistical model.

resultTen eligible studies that described the effectiveness of [⁶⁸Ga]Ga-FAPI PET imaging in breast, ovarian, and cervical cancers were included in this review. The total number of participants was 253 females. Aggregated data from nine studies indicate a remarkably high diagnostic odds ratio (DOR) of 48.69 (95% CI: [16.94-139.96]) for detecting primary tumors, and a DOR of 207.50 (95% CI: [46.18-932.34]) from seven studies for detecting lymph node metastasis. [⁶⁸Ga]Ga-FAPI PET demonstrated high diagnostic accuracy in identifying both primary lesions and metastatic lymph nodes in breast, ovarian, and cervical cancers.

conclusion[68Ga]Ga-FAPI PET imaging could function as a supplementary technique to [18F]F-FDG PET imaging modalities, offering a more comprehensive evaluation for cancer staging, assessment of treatment response, and guidance in radiation therapy planning.

Indexed as

Breast NeoplasmsGallium RadioisotopesOvarian NeoplasmsPositron-Emission TomographyRadiopharmaceuticalsUterine Cervical NeoplasmsFemaleHumansLymphatic MetastasisQuinolines68Ga-FAPIGallium RadioisotopesQuinolinesRadiopharmaceuticals[68Ga]Ga-FAPI-04 PET[68Ga]Ga-FAPI-46 PETbreast cancerCervical cancerOvarian Cancer

Identifiers

PMID41945933
PMCPMC13609139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.